China

采访 | Interview
王文胜先生
北京德彦兴业科贸有限公司 总经理

作为德彦兴业的总经理和创始人,您认为公司的核心业务是什么?
我们公司的核心业务是放射性同位素的供应,我们目前已和国际上的多家放射源厂家和国内的200余家用户单位建立了良好的合作关系。我们在国内的客户主要包括:医院、放射性药物生产企业、科研单位、高校实验室、工矿和油田企业、核仪器仪表企业以及其他需要使用或进口放射性同位素的单位和机构。

您如何看待放射性药物市场,例如,放射性元素进口在未来几年的发展?
我们认为中国在未来几年,医用的放射性同位素会呈一个增长的态势,来源主要还是依靠进口。

在您看来,中国工厂和医院是否已经成熟到足以推动这个市场的发展?是否能和外资企业合作了呢?
在我们看来,中国工厂和医院还未成熟到足以推动这个市场的发展。
但中国工厂和医院已经做好了准备,可以和外资企业合作。

在您眼中,为外资/比利时企业提供最优机遇的是哪些具体部门?换句话说,现如今中国医院的主体需求是什么?
我们认为在中国核医学领域:1. F‐18FDG 的诊断价格太高,市场需要低价同效的产品。Tc‐99m标记药物在中国价廉物美,但缺乏新的肿瘤方面的显像剂。2. 在肿瘤治疗方面,完成注册的药物太少,医师缺乏治疗的手段,市场需要新的有特异性的治疗药物。

中国法规是否为国外放射治疗及核医学产品的进口和注册提供了便利呢?
我们认为,中国核医药的进口和注册,在程序上与国际上类似,但在时间上可能会更长。但国际上的公司不能因在中国的注册所花费的时间长,就不走注册这一流程。因为你不注册就意味着永远不能进入中国市场。

您第一次听说Rad4Med.be是什么时候?
是在2014 年2~3 月从上海BioWin得知的。

您一共参加过2Rad4Med.be论坛,第一次是20145月在上海,第二次是201411月在比利时Biowin日上。可以说您的业务得益于此,对吗?
我们的业务近期与Rad4Med.be 论坛没有太多关系,但我们更看重远期。

您会推荐其他中国公司代表、医师、放射治疗及核医学部门的负责人加入Rad4Med.be吗?
我们会!

IBA signs contract to install first proton therapy center in North China
Contract worth more than EUR 80 million to IBA

IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has received a significant up-front payment for a new contract with the Zhuozhou Jian Kang Qiao Investment Company Ltd, to establish a proton therapy center in Zhuozhou City, Hebei Province, China. The center will be the first Proton Therapy Center in North China, situated 30 minutes from Beijing and it is expected to treat up to 2000 patients per year. The contract was signed at the end of 2014 and is worth more than EUR 80 million to IBA including the service contract. This does not impact the Company’s guidance for 2014 given at the time of the third quarter results. Read press release

中比在核医学和放射疗法的合作
2014年5月6日于上海
应用于放射医疗保健的比利时网络Rad4Med.be, 正在中国市场打下它的标记。


Rad4Med.be signed LOI in China
今 年5月6日,在中国上海,由Rad4Med.be、比利时驻上海总领事馆、上海聚科生物园区协办,在比利时瓦隆州经济商务处和BioWin的支持下举行的 中比核医学和放射疗法合作论坛上,比利时和中国的关键利益相关者值此契机签署了一份关于学术与产业合作的意向书。比利时Rad4Med.be由此达到了一 座里程碑。 更多

 

Rad4Med.be, the Belgian network for all applications of radiation in healthcare, is making its mark on the Chinese market.

Rad4Med.be signed LOI in ChinaRad4Med.be (Belgium) reached a milestone last May 6th in Shanghai (P.R. China) where a Letter of Intent about academic and industrial cooperation was signed between Belgian and Chinese key stakeholders on the occasion of the first Sino-Belgian Nuclear Medicine and Radiotherapy Cooperation Forum, co-hosted by Rad4Med.be, The Consulate General of Belgium in Shanghai and the Shanghai Juke Biotech Park with the support of the Walloon Trade and Invest Agency and BioWin. Read the press release

CZB-IBA contract signing ceremony

CZB-IBA contract signing ceremony - Belgium in ChinaAn agreement of cooperation has been signed by Beijing Zhibo-medical Biology Technology Company (CZB) and IBA during a ceremony in CZB’s Beijing headquarters on 26 August 2013. The Belgian embassy was represented at the ceremony supporting Belgium-China economic and technology cooperations such as this oneIBA is a world famous anti-cancer enterprise headquartered in Louvain-la-Neuve, Belgium and is the worldwide technology leader in the field of proton therapy. It is the first time in China that CZB high-tech company committed to production, distribution, diagnosis and management of IBA’s radiopharmaceutical products, such as the fully integrated IntegraLab solution to resolve the clinical needs of Beijing and other major cities. It has laid a solid foundation for CZB to set up over 10 R&D, production and distribution centers of radionuclide imaging, diagnosis and treatment, improve radionuclide therapy, establishing a nationwide network, form a specialized, standardized service management system, as well as to promote Nuclear Medicine and Cancer fighting industry in China.
Source:http://www.belgiuminchina.org/en/news/item/427-czb-iba-contract-signing-ceremony-.html

A centralised radiopharmacy project for the treatment of liver cancer in China

Since 2009, BioWin has successfully implemented a development strategy for its activities in China. One of the cluster’s achievements is the appointment of a permanent representative of BioWin in Shanghai. He is responsible for supporting Walloon SMEs in the health sector who want to develop their business in China, and preparing for the arrival of delegations of BioWin members coming to international trade shows in China. He is also responsible for setting up networking events, some of which have resulted in the signature of partnerships with the Juke Biotech Park in October 2011 and with the SBIA (Shanghai Biopharmaceutical Industry Association) in June 2010 and renewed in 2012. A fantastic example of this success is the fact that the company IRE -ELiT, based in Fleurus, has entered into negotiations with Jiangsu Lai Tai Medical Biotechnology Co. Ltd, a key player in China, whom they met in 2011, with a view to signing a research agreement in the field of radiopharmacy. Interview with Philippe van Put, Business Unit Radiopharmaceuticals & Business Development Manager at IRE-ELiT: « BioWin’s permanent representative in Shanghai plays a vital role : he helps us research and select partners. He also advises us on the China-Wallonia Innovation Platform (PIC-W) for the implementation of intellectual property protection in Asia, and in China in particular. His support is crucial for the development of our business in this part of the world, where a local presence is essential. We actually provide radioactive active ingredients that are combined with vectors to create treatments for tumours. Asia is a particularly important market as it is home to 80 % of the world’s cases of liver cancer« . Source: BioWin

Une réflexion au sujet de « China »

  1. Ping : Interview of Mr. Wang WenSheng CEO and founder of Beijing Deyan XingYe (BDXY) | Rad4Med.be

Les commentaires sont fermés.